Comparative analysis of PD‐1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL‐2 stimulation data by Daren Austin, Murad Melhem, Yash Gandhi, Sharon Lu, Sandra Visser

Get full text

A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042) by Xiaolong Tom Zhang, Hong Chen, Weiping Shao, Zhongping John Lin, Murad Melhem, Sharon Lu

Get full text

A Qualitative Approach to Understanding the Holistic Experience of Psychotherapy Among Clients by Lee Seng Esmond Seow, Rajeswari Sambasivam, Sherilyn Chang, Mythily Subramaniam, Huixian Sharon Lu, Hanita Ashok Assudani, Chern-Yee Geoffrey Tan, Janhavi Ajit Vaingankar

Get full text

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer by Victor E. Chen, BS, Erin F. Gillespie, MD, Kaveh Zakeri, MD, James D. Murphy, MD, Catheryn M. Yashar, MD, Sharon Lu, MD, John P. Einck, MD

Get full text

Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models by Sujatha Kumar, Srimoyee Ghosh, Geeta Sharma, Zebin Wang, Marilyn R. Kehry, Margaret H. Marino, Tamlyn Y. Neben, Sharon Lu, Shouqi Luo, Simon Roberts, Sridhar Ramaswamy, Hadi Danaee, David Jenkins

Get full text

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer by Wei Guo, Manish R Patel, Nashat Gabrail, Jordi Rodon, Erika Hamilton, Timothy A Yap, Meghan Duncan, Alberto Bessudo, Jasgit Sachdev, Lena Evilevitch, Sujatha Kumar, Sharon Lu, Bruce J Dezube

Get full text